2 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive CrisisCongenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Respiration Disorders, Urogenital Diseases, Vaso-Occlusive Crises, acute chest syndrome, acute kidney injury, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, kidney disorder, kidney failure, lung disorder, respiratory system disorder, sickle cell disease, urinary system disorderRecruitingPhase 22026-10-08NCT06699849
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CICCNS demyelinating autoimmune disease, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hernia, Infections, Neoplasms by Site, Neuroinflammatory Diseases, Paraneoplastic Syndromes, Nervous System, Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, central nervous system disorder, central nervous system infectious disorder, central nervous system malformation, demyelinating disease, immune system disorder, injury, meningocele, myelitis, neoplasm, nervous system disorder, nervous system injury, neurodegenerative disease, paraneoplastic syndrome, spinal cord disorder, spinal cord injuryRecruitingPhase 2 / Phase 32026-06-15NCT05491525